Stafford v. Rite Aid Corporation

CourtDistrict Court, S.D. California
DecidedFebruary 25, 2020
Docket3:17-cv-01340
StatusUnknown

This text of Stafford v. Rite Aid Corporation (Stafford v. Rite Aid Corporation) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Stafford v. Rite Aid Corporation, (S.D. Cal. 2020).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 BRYON STAFFORD, Individually and Case No.: 17-cv-1340-AJB-JLB on Behalf of All Others Similarly 12 ORDER DENYING DEFENDANT Situated, RITE AID CORPORATION’S 13 Plaintiff, MOTION TO COMPEL 14 v. ARBITRATION (Doc. No. 78) 15 RITE AID CORPORATION, Defendant. 16 17 Presently before the Court is Defendant Rite Aid Corporation’s (“Rite Aid”) motion 18 to compel arbitration. (Doc. No. 78.) Plaintiff Bryon Stafford (“Plaintiff”) opposed the 19 motion, (Doc. No. 86), and Defendant replied, (Doc. No. 88.) For the reasons set forth 20 below, the Court DENIES Rite Aid’s motion to compel arbitration. 21 I. BACKGROUND 22 Plaintiff brings a putative class action against Rite Aid for an alleged deceptive and 23 unfair pricing scheme involving Rite Aid’s Rx Savings Program. (Second Amended 24 Complaint (“SAC”), Doc. No. 30.) 25 As general background, the overwhelming majority of Rite Aid’s clients are enrolled 26 in either a private or public health care plan that covers some or all medical and 27 pharmaceutical expenses. (Id. ¶ 5.) In almost every one of these plans, the cost of 28 prescription drugs is shared between the third-party payor (i.e., the health insurance plan) 1 and the actual user of the drug (i.e., the plan participant). (Id.) When a plan participant fills 2 a prescription at a pharmacy under a third-party health care plan, the plan pays a portion of 3 the cost, and the plan participant pays the remaining portion of the cost directly to the 4 pharmacy as a copayment. (Id. ¶ 6.) Because of the cost savings associated with generic 5 drugs as opposed to brand name, third-party payors incentivize plan participants to 6 purchase generic drugs by offering a lower price, which in turn, results in a lower 7 copayment. (Id.) By law, Rite Aid cannot charge a copayment that exceeds its “usual and 8 customary” price, which is generally defined within the pharmaceuticals industry. (Id. ¶ 7.) 9 The process by which financial responsibility between third-party payors and plan 10 participants is determined is called “adjudication.” Rite Aid contracts with pharmacy 11 benefit managers (“PBMs”) and third-party payors (“TPPs”) to “adjudicate” the claims of 12 customers for prescription drug coverage. (Doc. No. 78-1 at 7.) The contracts specify Rite 13 Aid’s obligations to the TPP or PBM when submitting claims for prescription coverage at 14 the point of sale, as well as the amount Rite Aid will receive as payment when filling 15 prescriptions. (Id. at 8.) Generally, the TPP or PBM determines the amount of 16 reimbursement according to those contracts as well as the copayment or deductible amount. 17 (Id.) The TPP or PBM then transmits the information back to Rite Aid, instructing Rite Aid 18 on the amount to collect from the customer. (Id.) 19 Plaintiff alleges Rite Aid overcharges customers for generic prescription drugs by 20 submitting to TPP/PBMs claims for payment at prices that Rite Aid has inflated above its 21 “usual and customary” prices. (SAC ¶ 8.) As a result, Plaintiff claims customers who 22 purchase generic prescription drugs through third-party plans pay copayments that are 23 significantly higher than Rite Aid’s “usual and customary” prices for those same drugs. 24 (Id.) Central to this scheme, according to Plaintiff, is the Rx Savings Program. (Id. ¶ 9.) 25 The Rx Savings Program allows cash-paying customers (customers who pay for 26 prescription drugs without using insurance) to buy the most commonly prescribed generic 27 drugs at significantly discounted prices. (Id.) The Rx Savings Program prices, as contended 28 by Plaintiff, are often significantly lower than the prices Rite Aid reports to health 1 insurance companies as Rite Aid’s “usual and customary” prices. (Id.) Plaintiff claims Rite 2 Aid was required by law to report to the TPP/PBMs the Rx Savings Program prices as Rite 3 Aid’s “usual and customary” prices for the prescription generic drugs. (Id. ¶ 11.) The 4 failure to do so distorted the overall prescription calculations, resulting in higher copays to 5 customers. (Id.) Based on this alleged scheme, Plaintiff brings claims against Rite Aid for: 6 (1) negligent misrepresentation, (2) unjust enrichment, (3) violation of the Consumer Legal 7 Remedies Act (“CLRA”), (4) and violation of the California Unfair Competition Law 8 (“UCL”). 9 II. PROCEDURAL HISTORY 10 Plaintiff’s complaint was first filed in June 30, 2017. (Doc. No. 1.) A First Amended 11 Complaint was filed on July 28, 2017, (Doc. No. 18), and Rite Aid moved to dismiss for 12 failure to state a claim on Plaintiff’s four claims for relief. (Doc. No. 19.) In that motion, 13 Rite Aid also argued that Plaintiff’s claims were time-barred. (Id. at 31.) The Court granted 14 Rite Aid’s motion to dismiss without prejudice, holding that Plaintiff’s claims were time- 15 barred by their respective statutes of limitations. (Doc. No. 29.) The Court granted Plaintiff 16 leave to amend to provide further factual allegations to demonstrate that equitable tolling 17 applied to Plaintiff’s four causes of action. (Id.) Plaintiff filed a Second Amended 18 Complaint on January 9, 2018. (Doc. No. 30.) On January 23, 2018, Rite Aid moved to 19 dismiss the Second Amended Complaint for failure to state a claim. (Doc. No. 32-1.) On 20 September 28, 2018, the Court denied Rite Aid’s motion to dismiss, holding that Plaintiff 21 plausibly stated a claim on all four causes of action. (Id.) On June 17, 2019, Ride Aid filed 22 a motion to compel arbitration. (Doc. No. 78.) Plaintiff opposed, (Doc. No. 86), and Rite 23 Aid replied, (Doc. No. 88). This order follows. 24 III. LEGAL STANDARD 25 The Federal Arbitration Act (“FAA”) governs the enforcement of arbitration 26 agreements involving interstate commerce. See 9 U.S.C. § 2. Pursuant to § 2 of the FAA, 27 an arbitration agreement is “valid, irrevocable, and enforceable, save upon such grounds 28 as exist at law or in equity for the revocation of any contract.” Id. The FAA permits “[a] 1 party aggrieved by the alleged failure, neglect, or refusal of another to arbitrate under a 2 written agreement for arbitration [to] petition any United States district court . . . for an 3 order directing that such arbitration proceed in the manner provided for in [the] 4 agreement.” Id. § 4. 5 Given the liberal federal policy favoring arbitration, the FAA “mandates that district 6 courts shall direct parties to proceed to arbitration on issues as to which an arbitration 7 agreement has been signed.” Dean Witter Reynolds, Inc. v. Byrd, 470 U.S. 213, 218 (1985). 8 Thus, in a motion to compel arbitration, the district court’s role is limited to determining 9 “(1) whether a valid agreement to arbitrate exists and, if it does, (2) whether the agreement 10 encompasses the dispute at issue.” Kilgore v. KeyBank Nat’l Ass’n, 673 F.3d 947, 955–56 11 (9th Cir. 2012) (citing Chiron Corp. v. Ortho Diagnostic Sys., Inc., 207 F.3d 1126, 1130 12 (9th Cir. 2000)). If these factors are met, the court must enforce the arbitration agreement 13 in accordance with its precise terms. Id. 14 While generally applicable defenses to contract enforcement, such as fraud, duress, 15 or unconscionability, may invalidate arbitration agreements, the FAA preempts state law 16 defenses that apply only to arbitration or that derive their meaning from the fact that an 17 agreement to arbitrate is at issue. AT&T Mobility LLC v. Concepcion, 563 U.S. 333, 339 18 (2011).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Prima Paint Corp. v. Flood & Conklin Mfg. Co.
388 U.S. 395 (Supreme Court, 1967)
Dean Witter Reynolds Inc. v. Byrd
470 U.S. 213 (Supreme Court, 1985)
Kilgore v. KeyBank, National Ass'n
673 F.3d 947 (Ninth Circuit, 2012)
Mundi v. Union Security Life Insurance
555 F.3d 1042 (Ninth Circuit, 2009)
Goldman, Sachs & Co. v. City of Reno
747 F.3d 733 (Ninth Circuit, 2014)
United States v. Ortiz-Islas
829 F.3d 19 (First Circuit, 2016)
Paige Martin v. Gary Yasuda
829 F.3d 1118 (Ninth Circuit, 2016)
Esther Yang v. Dongwon Industries Co.
876 F.3d 996 (Ninth Circuit, 2017)
Jsm Tuscany, LLC v. Superior Court
193 Cal. App. 4th 1222 (California Court of Appeal, 2011)
Samson v. Nama Holdings, LLC
637 F.3d 915 (Ninth Circuit, 2010)
Fisher v. A.G. Becker Paribas Inc.
791 F.2d 691 (Ninth Circuit, 1986)

Cite This Page — Counsel Stack

Bluebook (online)
Stafford v. Rite Aid Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/stafford-v-rite-aid-corporation-casd-2020.